Advertisement

Clinical and Translational Oncology

, Volume 15, Issue 4, pp 321–326 | Cite as

Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin

  • Jaime Gómez-MillánEmail author
  • Maria Dolores Toledo
  • Yolanda Lupiañez
  • Antonio Rueda
  • Jose Manuel Trigo
  • Antonio Sachetti
  • Jose Antonio Medina
Research Article

Abstract

Background

This study analyzes the morbidity and the contribution of different causes of death to the outcome of patients with locally advanced head and- neck cancer after weekly cisplatin plus concomitant boost accelerated radiation treated in our center.

Materials and methods

Ninety-four patients with locally advanced head and neck carcinoma were included in this phase II trial consisting of concomitant boost radiation plus concurrent weekly cisplatin. The 43 patients treated in our centered with long-term follow-up were analyzed. Patients received radiotherapy with a concomitant boost scheme (1.8 Gy on days 1–40 and 1.5 Gy boost on days 25–40 with a total dose of 72 Gy) and concurrent cisplatin, 40 mg/m2 weekly, for the first 4 weeks.

Results

Most patients (93 %) received both radiation and complete chemotherapy according to protocol. Severe late toxicity presented were subcutaneous (5 %), larynx (2 %) and esophagous (5 %). Grade I–II late toxicity included mainly xerostomy (30 %), skin (16 %) and mucosal (16 %) toxicity. With a median follow-up of 95 months (9–135), the median overall survival and progression-free survival were 26 and 19 months, respectively (95 % CI 1–52; and 95 % CI 0–45); 60 % of the patients died because of head and neck cancer and 12 % of a second neoplasm, while 27 % of non-cancer patients died.

Conclusions

Patients with locoregionally advanced head and neck cancer treated with concomitant boost accelerated radiation plus chemotherapy show significant risks of mortality from causes other than disease progression.

Keywords

Head and neck cancer Late toxicity Accelerated radiation Concomitant boost radiation 

Notes

Conflict of interest

None.

References

  1. 1.
    Adelstein DJ, Li Y, Adams GL et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98PubMedCrossRefGoogle Scholar
  2. 2.
    Pignon JP, Bourhis J, Domenge C et al (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355:949–955PubMedGoogle Scholar
  3. 3.
    Pignon JP, le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4–14)Google Scholar
  4. 4.
    Corvo R (2007) Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 85:156–170PubMedCrossRefGoogle Scholar
  5. 5.
    Bernier J, Horiot JC (2012) Altered fractionated radiotherapy in locally advanced head and neck cancer. Curr Opin Oncol 24:1–6CrossRefGoogle Scholar
  6. 6.
    Rose BS, Jeong JH, Nath SK, Lu SM, Mell LK (2011) Population-based study of competing mortality in head and neck cancer. J Clin Oncol 29(26):3503–3509PubMedCrossRefGoogle Scholar
  7. 7.
    Medina JA, Rueda A, Sachetti A (2006) A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. Radiother Oncol 79:34–38PubMedCrossRefGoogle Scholar
  8. 8.
    Fu KK, Pajack TF, Trotti A et al (2000) A radiation therapy oncology group phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 2003. Int J Radiat Oncol Biol Phys 48:7–16PubMedCrossRefGoogle Scholar
  9. 9.
    Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214PubMedCrossRefGoogle Scholar
  10. 10.
    Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346PubMedCrossRefGoogle Scholar
  11. 11.
    Kim J, Tannock I (2005) Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5:516–525PubMedCrossRefGoogle Scholar
  12. 12.
    Bourhis J, Overgaard J, Audry H, Meta-Analysis of Radiotherapy in Carcinomas of Head and Neck (MARCH) Collaborative Group et al (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368:843–854PubMedCrossRefGoogle Scholar
  13. 13.
    Ang K, Zhang Q, Wheeler RH et al (2010) A phase III trial (RTOG 0129) of two radiation–cisplatin regimens for head and neck carcinomas (HNC): impact of radiation and cisplatin intensity on outcome [Abstract]. J Clin Oncol 28(Suppl 15):A-5507 Google Scholar
  14. 14.
    Bourhis J, Sire C, Lapeyre M et al (2008) Accelerated versus conventional radiotherapy with concomitant chemotherapy in locally advanced head and neck carcinomas: results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 72:S31–S32CrossRefGoogle Scholar
  15. 15.
    Blanchard P, Catherine H, Guihenneuc-Jouyaux C (2011) Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. J Clin Epidemiol 64:985–992PubMedCrossRefGoogle Scholar
  16. 16.
    Veldeman L, Madani I, Hulstaert F, De Meerleer G et al (2008) Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol 9:367–375PubMedCrossRefGoogle Scholar
  17. 17.
    Allen AM, Elshaikh M, Worden FP et al (2007) Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer. Head Neck 29:137–142PubMedCrossRefGoogle Scholar
  18. 18.
    Ang KK, Harris J, Garden AS et al (2005) Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation Therapy Oncology Group phase II trial 99-14. J Clin Oncol 23:3008–3015PubMedCrossRefGoogle Scholar
  19. 19.
    Newlin HE, Amdur RJ, Riggs CE et al (2010) Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer. Cancer 116:4533–4540PubMedCrossRefGoogle Scholar
  20. 20.
    Argiris A, Brockstein B, Haraf DJ et al (2004) Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 10(15):1956–1962PubMedCrossRefGoogle Scholar
  21. 21.
    Corry J, Peters LJ, Rischin D (2010) Optimising the therapeutic ratio in head and neck cancer. Lancet Oncol 11:287–291PubMedCrossRefGoogle Scholar
  22. 22.
    Rose B, Jong-Hyeon J, Nathe SK (2011) Population based study of competing mortality in head and neck cancer. J Clin Oncol 29(26):3503–3509PubMedCrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2012

Authors and Affiliations

  • Jaime Gómez-Millán
    • 1
    Email author
  • Maria Dolores Toledo
    • 1
  • Yolanda Lupiañez
    • 1
  • Antonio Rueda
    • 2
  • Jose Manuel Trigo
    • 3
  • Antonio Sachetti
    • 4
  • Jose Antonio Medina
    • 1
  1. 1.Radiation Oncology DepartmentHospital Clinico Universitario Virgen de la VictoriaMálagaSpain
  2. 2.Medical Oncology DepartmentHospital Costa del Sol MarbellaMálagaSpain
  3. 3.Medical Oncology DepartmentHospital Clinico Universitario Virgen de la VictoriaMálagaSpain
  4. 4.Radiation Oncology Department Centro radio-oncológico andaluz (CROASA)MálagaSpain

Personalised recommendations